NCT05456854

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an hyperglycemic clamp

Detailed description

Assignment: Each study subject will serve as their own control. The order of the visits will be randomized. Delivery of Interventions: Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. During the inpatient study, the subjects will Undergo a 16-hour kisspeptin infusion Undergo a hyperglycemic clamp

Conditions

• Metabolic Disease

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Hyperglycemic Clamp	Administration of a hyperglycemic clamp
DRUG	Kisspeptin-10	Administration of kisspeptin-10 \* 16 hr
DRUG	Placebo	Administration of placebo \*16 hr

Timeline

• Start date: 2022-06-03
• Primary completion: 2024-08-01
• Completion: 2024-08-01
• First posted: 2022-07-13
• Last updated: 2024-08-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study